Federal Circuit Refines Obviousness Framework for Drug and Biologic Dosing Regimens
By EsqSocial Corporation 09/04/25
The United States Court of Appeals for the Federal Circuit recently affirmed a district court ruling that a pharmaceutical dosing claim limitation was unpatentable due to obviousness-type double patenting. The court found that the “reasonable expectation of success” for the obviousness standard can be met even when there are fact-based differences between the claimed dosing regimen and prior art....
By: DLA Piper